Rallybio (NASDAQ:RLYB) Major Shareholder Purchases $491,414.00 in Stock

Key Points

• Adar1 Capital Management bought 35,101 Rallybio shares on May 5 at an average of $14.00 (≈$491,414), raising its stake to 779,784 shares (a 4.71% increase); the firm also purchased 120,804 shares on May 4 for about $1.69M.
• Rallybio shares traded up ~2% to $14.56 with a market cap of ~$77M and a 50‑day SMA of $9.01, institutional investors own about 90.34% of the stock, and the consensus analyst rating remains a Sell.

Rallybio Corporation (NASDAQ:RLYB - Get Free Report) major shareholder Adar1 Capital Management, Llc purchased 35,101 shares of the stock in a transaction dated Tuesday, May 5th. The shares were purchased at an average price of $14.00 per share, with a total value of $491,414.00. Following the completion of the transaction, the insider owned 779,784 shares of the company's stock, valued at approximately $10,916,976. This trade represents a 4.71% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Monday, May 4th, Adar1 Capital Management, Llc bought 120,804 shares of Rallybio stock. The shares were purchased at an average cost of $13.97 per share, for a total transaction of $1,687,631.88.

Rallybio Trading Up 2.0%

Rallybio stock traded up $0.28 during midday trading on Wednesday, reaching $14.56. 238,233 shares of the stock traded hands, compared to its average volume of 611,199. The firm has a market cap of $77.02 million, a PE ratio of -5.69 and a beta of -1.10. The company has a 50-day simple moving average of $9.01 and a two-hundred day simple moving average of $6.58. Rallybio Corporation has a 12-month low of $2.16 and a 12-month high of $15.31.

Rallybio (NASDAQ:RLYB - Get Free Report) last issued its quarterly earnings results on Monday, March 16th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.04) by $0.01. Rallybio had a negative net margin of 1,046.39% and a negative return on equity of 56.93%. The company had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.10 million.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of RLYB. Citadel Advisors LLC boosted its holdings in shares of Rallybio by 576.1% in the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company's stock valued at $219,000 after buying an additional 373,821 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Rallybio by 16.9% in the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company's stock valued at $573,000 after buying an additional 120,892 shares in the last quarter. Susquehanna International Group LLP boosted its holdings in shares of Rallybio by 485.9% in the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company's stock valued at $68,000 after buying an additional 113,031 shares in the last quarter. XTX Topco Ltd boosted its holdings in shares of Rallybio by 64.6% in the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company's stock valued at $67,000 after buying an additional 38,205 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Rallybio by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company's stock valued at $170,000 after buying an additional 2,996 shares in the last quarter. Institutional investors and hedge funds own 90.34% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised shares of Rallybio to a "hold" rating in a research report on Saturday, March 28th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Rallybio currently has a consensus rating of "Sell".

About Rallybio

Rallybio Therapeutics, Inc NASDAQ: RLYB is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company's scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio's pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio's lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.